Just a moment, the page is loading...
To report an adverse event or product complaint please call 844-4-SAGERX
 

Funding & Giving

Sage supports people and organizations that come together to create positive, lasting change.

Working together, Sage believes we can achieve our mission to pioneer solutions to help deliver life-changing brain health medicines, so every person can thrive. We offer grants and sponsorships to organizations and initiatives aligned with our mission and strategy.

Grants & Sponsorships

Where possible, Sage seeks to support the work of scientists, researchers, and community-based organizations aligned with our mission with select grants, sponsorships, and other funding opportunities. All funding requests must follow Sage's internal policies and procedures, as well as all applicable laws, regulations, and industry codes. Sage will not support requests from organizations that discriminate on the basis of age, political affiliation, race, national origin, ethnicity, gender, disability, sexual orientation or religious beliefs.

The following information provides more context regarding the types of requests Sage will consider funding and is most likely to accept. Please note that Sage will only consider funding and giving requests made through the request forms linked to this site. While we appreciate each request we receive, Sage cannot support every application for funding. All decisions are final.

Disease States

  • Major Depressive Disorder (MDD)
  • Postpartum Depression (PPD)
  • Huntington’s Disease (HD)
  • Parkinson’s Disease (PD)
  • Alzheimer’s Disease (AD)

Depression Franchise

  • Major Depressive Disorder (MDD)

    • Potential impact and effect of treating depression as an episodic medical disorder
    • Understanding the burden and effect of untreated depression on patient outcomes
    • Advances in technology for monitoring individuals with MDD
    • Advances in the understanding of the pathophysiology of MDD
    • Understanding neuroactive steroids (NAS), their potential role in MDD, and how they are distinct from standard of care antidepressant treatments (SOC ADTs)
    • Impact on GABA-A receptor modulation
    • Understanding burden of MDD disease and current treatments
    • Impact of delayed and/or suboptimal treatment on patient outcomes
    • Defining optimal patient outcomes, including potential role for rapid acting treatment of MDD
    • Patient perspectives and communication on burden of disease and management of MDD
  • Postpartum Depression (PPD)

    • Impact of delayed PPD diagnosis and treatment on patient outcomes
    • Increasing external knowledge of the at-risk PPD patient population, and the need for medically appropriate screening and diagnosis
    • Advances in the understanding of the pathophysiology of PPD
    • Understanding and appropriately addressing the stigma of PPD on patients
    • Understanding neuroactive steroids (NAS) and their potential role in PPD
    • Understanding burden of PPD, current and future treatments, and outcomes
    • Understanding the generational effects of untreated PPD on families and communities
    • Long term impact of PPD to child development
    • Review of clinical and real-world evidence supporting current and future treatments for PPD
    • Patient perspectives and communication on burden of disease and management of PPD

Education for HCPs, including but not limited to the following audiences:

  • Psychiatrists, Primary Care Mental Health Specialists, Neurologists, Mental Health Specialists, Psychiatric NP/PAs, Clinical Psychologists (MDD)
  • OB/GYN, Psychiatrists, Maternal Fetal Medicine, Primary Care Mental Health Specialists, Perinatal Psychiatrists, Psychiatric NP/PAs, Clinical Psychologists (PPD)

Format (to support broad, interactive education)

  • US-based grant applications
  • Digital-Enduring
  • Live education with enduring component

Neuropsychiatry Franchise

  • Huntington's Disease (HD)
    • The hypothesized implications of N-methyl-D-aspartate (NMDA) neuropathology in HD
    • NMDA neurobiology and pharmacology, including its potential relation to cognitive improvement
    • Clinical phenomenology (e.g., impact on executive functioning) of mild cognitive impairment in HD and the impact of delayed treatment for cognitive impairment in HD
    • Cholesterol dysregulation and the hypothesized role of neuroactive steroids (NAS) in HD
    • Current/future treatment landscape for non-motor/movement aspects of HD
    • Multi-systemic nature of HD and impact of multidisciplinary diagnosis and management
  • Parkinson's Disease (PD)
    • Cognitive symptoms and current/future treatment landscape in PD
    • Clinical phenomenology (e.g., impact on executive functioning) in PD
    • Impact of delayed treatment for cognitive impairment in PD
    • Assessment and diagnosis of mild cognitive impairment (MCI)/cognitive changes in PD
  • Alzheimer's Disease (AD)
    • Understanding the frequency and magnitude of executive functioning deficits across the spectrum of AD (sub-clinical, MCI, dementia)
    • Impact of delayed treatment of cognitive symptoms associated with AD
    • Understanding cognitive symptoms and current treatments in AD
  • Education for HCPs, including but not limited to the following audiences:
    • Movement Disorder Specialists, Neurologists and Psychiatrists (HD, PD, AD)
  • Format (to support broad, interactive education)
    • US-based grant applications
    • Digital-Enduring
    • Live education with enduring component

Educational grant requests must conform to the following:

  • Grant requests must be unsolicited, should have multiple funders, and must not provide nor promise any benefit to Sage.
  • Educational programs, activities, or materials that are designed to promote the institution’s or organization’s bona fide patient or educational services must relate to an area of interest to Sage.
  • Funding amounts must be reasonable for the activities proposed and grant funds must only be used for the expenses described in the grant application and the approval agreement.

Educational grant requests may NOT:

  • Be payable to an individual HCP or physician practice, or companies predominantly owned by a practicing individual HCP or his/her spouse, or the charitable arm thereof.
  • Request use of funding to support conference travel grants or registration fees for HCPs (other than funding of scholarships to permit medical students, residents, fellows or other HCPs in training to attend carefully selected educational conferences without naming the recipient).
  • Be for education that is routine and/or a required part of medical training, e.g. textbooks, journal subscriptions, or preparation materials for Board reviews.
In 2022, grant submissions will be reviewed on a quarterly basis. Below are timeframes for the quarterly reviews and corresponding submission deadlines:
Q1 Grants submission deadline: January 15th
Q1 Grants review: Mid-March
Q2 Grants submission deadline: April 1st
Q2 Grants review: Mid-June
Q3 Grants submission deadline: July 1st
Q3 Grants review: Mid-September
Q4 Grants submission deadline: October 1st
Q4 Grants review: Mid-December

Funding decisions for grants are made through a formal, centralized grant review and decision-making process.

In all cases, Sage notifies applicants of decisions by email. All applications recieve a fair review, and we encourage organizations to reapply for future programs and initiatives.



Apply Now

If you have any questions, please email grants@sagerx.com.

Sponsorship requests:

  • must clearly identify the benefit offered to Sage.
  • must include sponsorship benefits and any amount requested must be reasonable for the activities proposed and consistent with comparable meetings or events.
  • must be made available to multiple organizations, and not just to Sage.

All sponsorship requests will be reviewed on an ongoing basis. Funding decisions for sponsorships are made through a formal, centralized review and decision-making process.

In all cases, Sage notifies applicants of our decision by email. All applications receive a fair review, and we encourage organizations to reapply for future programs and initiatives.



Apply Now

If you have any questions, please email sponsorship@sagerx.com.

Investigator Initiated Research (IIR) Grants

Sage is committed to helping support Investigator Initiated Research (IIR) that furthers scientific and clinical understanding of life-altering brain health disorders. IIR is research that is initiated, sponsored and conducted by an external investigator or institution. IIR requests may include funding, drug supply, or both. Sage’s IIR program is managed by an internal IIR Committee and is governed by Sage’s internal policies and procedures. All decisions are final.

Brexanolone IIR Areas of Interest

  • Women's Health
    • PPD Prophylaxis (History of Depression)
    • Postpartum Psychosis
    • Postpartum Obsessive-Compulsive Disorder (OCD)
    • Antenatal Depression (treatment initiation postpartum day 1 or 2 for antenatal onset of depression)
  • PPD Well-being & Functioning
    • Mother/Family Health-related Quality of Life (HRQoL) and Functioning
    • Child (Well Baby Outcomes)
    • Effects on sleep architecture
  • Other Neuropsychiatric and Neurologic Conditions (e.g., tinnitus, acute Post-traumatic stress disorder, Panic Disorder, COVID-19 infection-related neurological sequelae, involuntary speech disorders, substance abuse disorders, catatonia)
  • Preclinical (e.g. imaging, neuronal remodeling, signaling pathways)


Apply Now

If you have any questions, please email grants@sagerx.com.


Report Adverse Event

If you have an adverse event or product complaint to report, please call 844-4-SAGERX


©2022 Sage Therapeutics, Inc. All rights reserved.
SAGE THERAPEUTICS, ZULRESSO and their respective logos, and SAGE CENTRAL are registered trademarks of Sage Therapeutics, Inc. All other trademarks referenced herein are the property of their respective owners.
MRC-ZUL-00155 10/21